Related Experiment Video
Updated: Mar 2, 2026
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial
Mohammed D Saleem1, Deborah Negus1, Steven R Feldman1,2,3
1a Department of Dermatology, Wake Forest School of Medicine , Center for Dermatology Research , Winston-Salem , NC , USA.
Background:
Traditionally, ointments were the vehicle of choice for psoriasis. Poor adherence of traditional vehicles limits the use of topical corticosteroids. Alternative formulations have gained popularity due to their ease of application, improved adherence and efficacy.
Objective:
To evaluate the efficacy of topical desoximetasone 0.25% spray formulation in extensive psoriasis.
Methods:
This multicenter, double-blinded, randomized trial compared twice daily topical 0.25% desoximetasone spray to placebo in subjects ≥18 with moderate to severe plaque psoriasis. Primary outcome of the study was the proportion of subjects in each group that achieved clinical success (Physician Global Assessment [PGA] of 0 or 1) and/or treatment success at (target lesion score of 0 or 1) day 28.
Results:
One-hundred-and-twenty subjects were enrolled. At baseline, 75.0% and 73.3% of the treatment and placebo group had at least moderate PGA, respectively. Clinical success in the intended-to treat and placebo group was 30% and 5% (p = .0003), respectively; treatment success was 39% and 7% (p < .0001), respectively.
Limitations:
The lack of standardized outcomes for topical psoriasis treatments limits the ability to compare the results to other treatments.
Conclusions:
Topical desoximetasone spray provides rapid control of moderate to severe psoriasis lesions and may be considered for patients awaiting approval of biologicals.
Trial Registration:
Clinical Trial was registered at clinicaltrial.gov: NCT01206387.
